Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — clinical trials in Spain
30 open options
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
ITI-1284 · Placebo — 70 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 159 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Placebo (Study Part 1a) · ACI-24.060 at Dose A in Study Part 1a · ACI-24.060 at Dose B in Study Part 1a — 26 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALNARECRUITING
Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders
Cognitive behavioral therapy with in vivo exposure · Cognitive behavorial therapy with in vivo exposure plus SYMPTOMS-JIT — 1 site
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALNARECRUITING
Study of the Brain's Natural Cleaning System in Potential Organ Donors.
Indocynanine Green meningeal injection to understand anatomical connection from the meningeal lymphatic system to the cervical lymph nodes — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE2 / PHASE3RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACP-204 · Placebo — 148 sites
- TRIALNANOT_YET_RECRUITING
Effects of Resistance and Dual-Task Training on Physical, Oculomotor, and Executive Functions in Older Adults With MCI
Anaerobic therapeutic exercises (resistance exercise) · Anaerobic therapeutic exercises (resistance exercise) plus Dual Task — 2 sites
- TRIALNANOT_YET_RECRUITING
Benefits of Strength Training in Informal Caregivers of Patients With Alzheimer's Disease
Progressive Muscle Relaxation · Functional Strength Training — 1 site
- TRIALNAENROLLING_BY_INVITATION
Home-Based Closed-Loop Auditory Stimulation to Enhance Slow-Wave Activity in MCI Due to Alzheimer's Disease: A Proof-of-Concept Study
Closed-Loop Auditory Stimulation — 1 site
- TRIALPHASE3NOT_YET_RECRUITING
Masitinib in Patients With Mild Alzheimer's Disease
Placebo · Masitinib (4.5) · Standard of care — 9 sites
- TRIALPHASE1RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
RO7812653 · Placebo — 12 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
ALN-5288 · Placebo — 13 sites
- TRIALPHASE3RECRUITING
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Levetiracetam 500mg · Placebo — 5 sites
- TRIALNANOT_YET_RECRUITING
Evaluation of a Digital Neurorehabilitation Program Using Exergames for Adults With Mild Cognitive Impairment
Digital exergame-based neurorehabilitation program · Individual conventional physiotherapy — 1 site
- TRIALNARECRUITING
Effect of a Probiotic Formula in Mild Cognitive Impairement
Probiotic Arm · Placebo — 2 sites
- TRIALNARECRUITING
Significant Activities in the Integrated Person-centered Care Model
meaningful activities · other activities — 1 site
- TRIALNANOT_YET_RECRUITING
Intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer
Multimodal intervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer — 1 site
- TRIALNANOT_YET_RECRUITING
Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI
Plase-Locked Acoustic Stimulation during slow-wave sleep · Phase-locked acoustic stimulation-Sham condition — 1 site
- TRIALPHASE3NOT_YET_RECRUITING
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
tributyrin · Placebo — 1 site
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALNARECRUITING
Effects of a Computerized Cognitive Stimulation Intervention Adapted to the Level of Cognitive Reserve
Computerized cognitive stimulation program · Face-to-face training-explanatory session — 1 site
- TRIALPHASE3ENROLLING_BY_INVITATION
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACP-204 — 76 sites
- TRIALNANOT_YET_RECRUITING
Prevention of ANxiety and Depression Over Risk Assessment
Pandora-1 app with high levels of personalization, interaction, monitoring and feedback · Pandora-2 app with low levels of personalization, interaction, monitoring and feedback — 1 site
- TRIALPHASE2RECRUITING
Open-label Extension Study in Participants With Early Alzheimer's Disease
GSK4527226 — 33 sites
- TRIALNARECRUITING
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
Video-Implemented Script Training for Aphasia (VISTA) · Lexical Retrieval Training (LRT) — 3 sites
- TRIALNANOT_YET_RECRUITING
Effectiveness of Genistein in Mild Cognitive Impairment
Genistein · Control product placebo — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.